Sunday, May 28, 2023
English News
  • Hyderabad
  • Telangana
  • Andhra Pradesh
  • India
  • World
  • Entertainment
  • Science and Tech
  • Sport
  • Business
  • ...
    • NRI
    • View Point
    • cartoon
    • Columns
    • Reviews
    • Education Today
    • Property
    • Videos
    • Lifestyle
    • Rewind
E-Paper
  • NRI
  • View Point
  • cartoon
  • Columns
  • Reviews
  • Education Today
  • Property
  • Videos
  • Lifestyle
  • Rewind
Home | Health | Effective Drug For Metastatic Papillary Kidney Cancer

Effective drug for metastatic papillary kidney cancer

The findings, to be published in the journal The Lancet, found that patients receiving sunitinib went a median of 5.6 months before their cancer progressed; patients receiving savolitinib and crizotinib

By IANS
Updated On - 03:04 PM, Sun - 14 February 21
Effective drug for metastatic papillary kidney cancer
whatsapp facebook twitter telegram

New York:Researchers have found that the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer among three targeted drugs.

The findings, to be published in the journal The Lancet, found that patients receiving sunitinib went a median of 5.6 months before their cancer progressed; patients receiving savolitinib and crizotinib fared much worse overall. But cabozantinib, which inhibits VEGF receptors and AXL in addition to MET, gave patients a median of 9.2 months before their cancer progressed, the study indicated.

“The magnitude of the response was surprising,” said researcher Sumanta Pal from the City of Hope in the US said. “We still have a long way to go to help make patients’ lives longer and better, but we do have a new standard treatment for these rare cancer patients,” Pal added.

Mutations in the MET gene are a hallmark of this type of cancer, and there are new drugs that target the MET gene among other important signalling pathways, the researcher said. For the study, the team studied 147 eligible patients with papillary kidney cancer, most of whom had not received any prior treatment.

Patients were randomly assigned to one of four treatment groups – those who took sunitinib and those who took one of the three MET target drugs — cabozantinib, crizotinib, and savolitinib. The team wanted to see how long it would take patients’ cancer to spread or return, a measure known as progression-free survival. In addition to the result, the team also found, 23 per cent of patients had a significant reduction in the size of their tumour with cabozantinib. In contrast, only 4 per cent of patients saw this kind of tumour response with sunitinib.

  • Follow Us :
  • Tags
  • Drugs
  • metastatic papillary kidney cancer
  • New York
  • Researchers molecule inhibitor cabozantinib

Related News

  • Telangana State Police invites entries for video contest with cash prizes

    Telangana State Police invites entries for video contest with cash prizes

  • US lawmaker introduces bill to declare Diwali as federal holiday

    US lawmaker introduces bill to declare Diwali as federal holiday

  • New York State Assembly to pass legislation to observe Diwali as federal holiday

    New York State Assembly to pass legislation to observe Diwali as federal holiday

  • Drugs worth Rs 3.14 crore seized in Nagarkurnool

    Drugs worth Rs 3.14 crore seized in Nagarkurnool

  • Kurt Cobain’s smashed guitar sells for record-breaking 5 crore at auction

    Kurt Cobain’s smashed guitar sells for record-breaking 5 crore at auction

  • Parul Chaudhary wins women’s 3000m steeplechase title in New York event

    Parul Chaudhary wins women’s 3000m steeplechase title in New York event

Latest News

  • Wrestlers protest: Over 700 detained, FIR registered against organisers

    4 hours ago
  • CBI lodges FIR against Bollywood producer Bunty Walia in loan fraud case

    4 hours ago
  • Turkiye’s Erdogan wins 5th term as president, extending rule into 3rd decade

    4 hours ago
  • Opinion: Economy up, jobs down

    4 hours ago
  • Editorial: Prison reforms overdue

    4 hours ago
  • Sengol has ‘bent’ the very first day: TN CM MK Stalin

    5 hours ago
  • GHMC’s DRF team completes training in rescue operations

    5 hours ago
  • US, Saudi Arabia call for warring sides in Sudan to extend ‘imperfect’ cease-fire

    5 hours ago

company

  • Home
  • About Us
  • Contact Us

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

© Copyrights 2022 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam